Journal
JOURNAL OF HEADACHE AND PAIN
Volume 20, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s10194-019-0974-3
Keywords
Migraine; Randomized clinical trial; Efficacy; Tolerability; Adverse event; Ditan; Gepant; Antibody
Categories
Funding
- Eli Lilly
Ask authors/readers for more resources
BackgroundIn the past decade, migraine research has identified novel drug targets. In this review, we discuss recent data on emerging anti-migraine therapies.Main bodyThe development of ditans, gepants and anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of migraine is one of the greatest advances in themigraine field. Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders. The monoclonal antibodies are migraine specific prophylactic drugs with high responder rates and favorable adverse event profiles. Furthermore, they offer convenient treatment regimens of 4- or 12-week intervals.ConclusionCollectively, novel migraine therapies represent a major progress in migraine treatment and will undoubtedly transform headache medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available